Direct phosphorylation of proliferative and survival pathway proteins by RET.
BACKGROUND
Gain-of-function mutations in the RET tyrosine kinase receptor cause the multiple endocrine neoplasia syndromes type 2a and 2b, and medullary thyroid cancer. We have previously shown that RET signals through focal adhesion kinase (FAK) in medullary thyroid cancer cells and that extracellular signal-regulated kinase (ERK) activity can be blocked by pp2, an inhibitor of both Src and RET. We hypothesized that RET could directly phosphorylate FAK and ERK.


METHODS
RET and ERK kinase activity were measured with the use of an in vitro kinase assay. The relative contribution of RET in phosphorylation of ERK was tested by treating cells with PD98059, an inhibitor of MEK, and the RET inhibitor PP2, then measuring ERK activity.


RESULTS
Immunoprecipitated, mutant RET from cells or the recombinant RET kinase domain was able to directly phosphorylate tyrosine residues on FAK. Specifically Y576/577, Y861, and Y925, but not the autophosphorylation site Y397 of FAK, were phosphorylated by RET. Similarly ERK 2 could be phosphorylated at Y187 (Y204 in ERK1). Inhibition of both MEK (upstream of ERK) and RET was more potent than inhibition of either alone in decreasing ERK activity. Furthermore, tyrosine residues in DOK1, the p85 subunit of phosphatidylinositol 3' kinase, JNK 1 and 2, P-38, and phospholipase-gamma were directly phosphorylated by RET.


CONCLUSIONS
RET directly phosphorylates tyrosine residues on FAK, ERK 1/2, DOK1, the p85 subunit of of phosphatidylinositol 3' kinase, JNK 1 and 2, P-38, and phospholipase-gamma. These data indicate a direct interaction between RET and a broad range of effector molecules that may contribute to tumor pathogenesis.
Panta
Ganesh R
GR
Central Arkansas Veterans Healthcare System, Department of Surgery, University of Arkansas for Medical Sciences, Little Rock, USA.
Du
Lihua
L
Nwariaku
Fiemu E
FE
Kim
Lawrence T
LT
D018276:Carcinoma, Medullary / Q000378:metabolism*; D045744:Cell Line, Tumor; D004791:Enzyme Inhibitors / Q000494:pharmacology; D048049:Extracellular Signal-Regulated MAP Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism; D005419:Flavonoids / Q000494:pharmacology; D051417:Focal Adhesion Kinase 1; D051416:Focal Adhesion Protein-Tyrosine Kinases; D006801:Humans; D010766:Phosphorylation; D011505:Protein-Tyrosine Kinases / Q000378:metabolism; D011518:Proto-Oncogene Proteins / Q000378:metabolism*; D051096:Proto-Oncogene Proteins c-ret; D020794:Receptor Protein-Tyrosine Kinases / Q000378:metabolism*; D015398:Signal Transduction / Q000502:physiology; D013964:Thyroid Neoplasms / Q000378:metabolism*; D014443:Tyrosine / Q000378:metabolism
D004791:Enzyme Inhibitors; D005419:Flavonoids; D011518:Proto-Oncogene Proteins; D014443:Tyrosine; D011505:Protein-Tyrosine Kinases; D051096:Proto-Oncogene Proteins c-ret; D020794:Receptor Protein-Tyrosine Kinases; D051417:Focal Adhesion Kinase 1; D051416:Focal Adhesion Protein-Tyrosine Kinases; C496050:PTK2 protein, human; D048049:Extracellular Signal-Regulated MAP Kinases; C093973:2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one